Resumo

GONZALEZ RIVAS, Juan Pablo  e  GARCIA SANTIAGO, Raúl José. Dislipidemias: Controversias del riesgo residual. Rev. Venez. Endocrinol. Metab. [online]. 2013, vol.11, n.2, pp.59-66. ISSN 1690-3110.

Statins are the principal treatment for highest levels of LDL cholesterol, with clear benefits in reduction of cardiovascular disease (CVD). However, although patients reach LDL cholesterol goal, 60% to 70% have a relative risk remnant of CVD, named Residual Risk. By this, the discussion is focused in other objectives beside LDL cholesterol, being the low HDL cholesterol and/or elevated triglycerides a relevant therapeutic target to reduce the residual risk. Many combinations of drugs have been associated to statins to optimize lipid profile. Most of these classics drugs (fibratos, niacin, and fatty acids omega-3) and the new drugs of Cholesteryl Ester Transfer Proteins inhibitors, increase HDL cholesterol and reduce triglycerides combined with statins, however, in mostly of cases these combinations have not reduced CVD; in studies with niacin, the combination increase deleterious effects despite the optimization of lipid profile. These facts make us reconsider the knowledge we have on dyslipidemia and its treatment, so we present the following review.

Palavras-chave : Residual Risk; controversies; dyslipidemia; hypertrigliceridemia; hypoalphalipoproteinemia.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )